Cargando…

How to compare antivirals in the treatment of chronic hepatitis B?

Detalles Bibliográficos
Autores principales:	Ozaras, Resat, Leblebicioglu, Hakan
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652423/ https://www.ncbi.nlm.nih.gov/pubmed/19254373 http://dx.doi.org/10.1186/1476-0711-8-6

Ejemplares similares

Hepatitis E virus infection in Turkey: a systematic review
por: Leblebicioglu, Hakan, et al.
Publicado: (2018)

COVID-19 pandemic and international travel: Turkey’s experience
por: Ozaras, Resat, et al.
Publicado: (2021)

Systematic review of COVID-19 and autoimmune thyroiditis
por: Tutal, Esra, et al.
Publicado: (2022)

Crimean-Congo haemorrhagic fever in travellers: A systematic review
por: Leblebicioglu, Hakan, et al.
Publicado: (2016)

COVID 19 and febrile neutropenia: Case report and systematic review
por: Kaya, Taner, et al.
Publicado: (2022)

COVID-19-associated mucormycosis: Case report and systematic review
por: Dilek, Ahmet, et al.
Publicado: (2021)

How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?
por: Loglio, Alessandro, et al.
Publicado: (2020)

More on hepatic granulomas
por: Ozaras, Resat, et al.
Publicado: (2015)

The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?
por: Jeng, Wen-Juei, et al.
Publicado: (2023)

Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib
por: Simão, Adélia
Publicado: (2016)

Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
por: Kim, Sung Eun
Publicado: (2017)

Primary care physicians' approach to diagnosis and treatment of hepatitis B and hepatitis C patients
por: Peksen, Yildiz, et al.
Publicado: (2004)

India's 'gold mine' of ancestral bacilli and the looming TB-HIV pandemic
por: Ahmed, Niyaz, et al.
Publicado: (2006)

Hemoptysis in COVID-19: Pulmonary Emboli Should be Ruled Out
por: Ozaras, Resat, et al.
Publicado: (2020)

How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?
por: Yu, Jung Hwan, et al.
Publicado: (2019)

Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
por: Adinolfi, Luigi Elio, et al.
Publicado: (2018)

Treatment of acute hepatitis C virus infection with interferon-α 2b and ribavirin: Case report and review of the literature
por: Leblebicioglu, Hakan, et al.
Publicado: (2002)

Detection of Hepatitis B Virus in Used Razor Blades by PCR
por: Eroglu, Cafer, et al.
Publicado: (2010)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Another oral antiviral treatment, but still far away from hepatitis B virus cure
por: Tseng, Tai-Chung
Publicado: (2021)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections(†)
por: De Clercq, Erik, et al.
Publicado: (2010)

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
por: Tillmann, Hans Ludger
Publicado: (2008)

Antiviral Treatment among Pregnant Women with Chronic Hepatitis B
por: Fan, Lin, et al.
Publicado: (2014)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Newly Reported Studies on the Increase in Gastrointestinal Symptom Prevalence withCOVID-19 Infection: A Comprehensive Systematic Review and Meta-Analysis
por: Akin, Hakan, et al.
Publicado: (2020)

Current Antiviral Therapy for Chronic Hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2004)

Antiviral therapy for chronic hepatitis B in China
por: Zheng, Xin, et al.
Publicado: (2014)

Management of Antiviral Resistance in Chronic Hepatitis B
por: Lim, Young-Suk
Publicado: (2017)

Advances in new antivirals for chronic hepatitis B
por: Tang, Yanhua, et al.
Publicado: (2022)

Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response
por: Heo, Jeong
Publicado: (2011)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019)

A Primary Giant Hydatid Cyst of the Ovary
por: Kaya, Abdurrahman, et al.
Publicado: (2012)

Coinfections among COVID-19 patients: A need for combination therapy?
por: Ozaras, Resat, et al.
Publicado: (2021)

Serum Hepatitis B Surface Antigen Levels and Their Utility as a Predictor of Sustained Virological Response After Antiviral Treatment
por: Karayiannis, Peter
Publicado: (2012)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Primary Hepatic Small-Cell Carcinoma Developed during Antiviral Treatment for Chronic Hepatitis B
por: Kim, Suk Bae
Publicado: (2015)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
por: Chien, Rong-Nan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_28hc1nj8fncts4kpqi67253mgq